43.16
-1.74 (-3.88%)
| Penutupan Terdahulu | 44.90 |
| Buka | 44.84 |
| Jumlah Dagangan | 384,508 |
| Purata Dagangan (3B) | 1,147,859 |
| Modal Pasaran | 2,580,985,600 |
| Harga / Buku (P/B) | 5.71 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 May 2026 |
| EPS Cair (TTM) | -1.92 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.23% |
| Nisbah Semasa (MRQ) | 21.07 |
| Aliran Tunai Operasi (OCF TTM) | -73.96 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -45.43 M |
| Pulangan Atas Aset (ROA TTM) | -21.36% |
| Pulangan Atas Ekuiti (ROE TTM) | -31.30% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Enliven Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.5 |
| Purata | 0.50 |
|
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven’s programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 4.75% |
| % Dimiliki oleh Institusi | 90.86% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Fairmount Funds Management Llc | 31 Dec 2025 | 3,711,444 |
| Novo Holdings A/S | 31 Dec 2025 | 1,480,000 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| COLLINS HELEN LOUISE | - | 48.11 | -5,000 | -240,550 |
| Jumlah Keseluruhan Kuantiti Bersih | -5,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -240,550 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 48.11 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| COLLINS HELEN LOUISE | Pegawai | 17 Apr 2026 | Jual automatik (-) | 5,000 | 48.11 | 240,550 |
| COLLINS HELEN LOUISE | Pegawai | 17 Apr 2026 | Pelaksanaan pilihan | 5,000 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |